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Abstract
Cytogenomic investigations of haematological neoplasms, including chromosome banding analysis, ﬂuorescence in situ
hybridisation (FISH) and microarray analyses have become increasingly important in the clinical management of patients
with haematological neoplasms. The widespread implementation of these techniques in genetic diagnostics has highlighted
the need for guidance on the essential criteria to follow when providing cytogenomic testing, regardless of choice of
methodology. These recommendations provide an updated, practical and easily available document that will assist
laboratories in the choice of testing and methodology enabling them to operate within acceptable standards and maintain a
quality service.
Introduction
Haematological neoplasms are classiﬁed according to
World Health Organisation (WHO) classiﬁcation of
tumours in myeloid and lymphoid tissues, some of which
are deﬁned by the presence of distinct genetic abnormalities
[1]. The detection of clonal abnormalities provides support
for a neoplastic or premalignant condition and provides
important prognostic and therapeutic information [2]. The
number of WHO haematological neoplasms deﬁned by
genetic abnormalities is steadily increasing as is the number
of speciﬁc treatment approaches that directly, or
indirectly, target genetic abnormalities. Therefore, genetic
analysis is an important element in diagnosis, classiﬁcation,
prognostication and monitoring disease response to
treatment.
Cytogenomic testing includes chromosome banding
analysis, ﬂuorescence in situ hybridisation (FISH) and
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microarray analyses, and these, together with mutation
screening, have become increasingly important in the
clinical management of patients. Testing strategies are
evolving where array-based techniques and genome wide
sequencing strategies are replacing karyotyping and FISH.
Currently these techniques are used as standalone tests, or
in combination, for evaluation of genetic abnormalities.
However new technologies, capable of simultaneously
detecting copy number changes, structural variants and
mutations, are now available and although these are not
currently being used in a diagnostic setting it is expected
that this approach will be increasingly used in the future.
Recommendations for other molecular testing are outside
the scope of this document and are not addressed here.
Preferably the results of both cytogenomic and molecular
genetics should be integrated to provide an overall com-
prehensive report stating, if relevant, the cytogenomic
prognostic information.
In 2013, speciﬁc guidelines for acquired cytogenetics
were published, [3] these are updated here to reﬂect changes
in practice. These recommendations were prepared by a
panel of 16 experts specialised in cytogenomic testing of
haematological neoplasms, all of whom are involved in
External Quality Assessments (EQA) for haematological
neoplasms. Each section was overseen by a sub-group of
the panel. All authors then gave their opinion and the text
was adapted in light of the panels’ replies. This process was
repeated several times until a consensus emerged. The
recommendations were then ﬁnalised in a group discussion.
Furthermore, opinions were sought from other experts in the
ﬁeld. These recommendations take into account the
experience of EQA, good laboratory practice documents,
accreditation standards and protocols from different coun-
tries, as well as international policy documents. These
recommendations apply unless overridden by national/fed-
eral laws, regulations and/or standards. In accordance with
the terminology recommended by the International System
for Human Cytogenomic Nomenclature (ISCN, 2016) [4]
cytogenomics is used as a general term in this document.
Speciﬁc designations are used when needed, otherwise the
global term applies. The use of terms such as ‘should’,
‘must’ or ‘essential’ are mandatory requirements (when not
in conﬂict with national law or regulations), while the use of
terms such as ‘may’ or ‘could’, are recommended but not
mandatory.
These recommendations aim to provide guidance on
testing priority and the most appropriate methodologies.
This document is organised in two sections: general and
speciﬁc recommendations. General recommendations
address essential criteria to follow when providing
cytogenomic testing and speciﬁc recommendations advise
on the choice of testing and preferred methodology for each
entity.
General recommendations
Essential testing can be achieved by different, or combined,
technological approaches. When deciding which method to
use, the referral indication plus the advantages and limita-
tions of each technique must be taken into account [5]. It is
recognised that laboratories have variable testing strategies
depending on available technology and that the testing
methodologies covered in these recommendations may be
superseded in the future. The methods discussed here
comprise the major methods currently used in cytogenomic
laboratories.
Service requirements regarding equipment, facilities,
staff and diagnostic workload must comply with ISO-15189
[6] standards. Laboratories should provide a robust analy-
tical and interpretive service for neoplastic referrals, have
written protocols/standard operating procedures (SOPs), for
all aspects of sample processing, based on in-house vali-
dated methodologies and/or published guidelines, and par-
ticipate in an appropriate EQAs. All pre- and post-analytical
procedures should also follow written protocols. These
guidelines are minimum requirements and professional
judgement is of paramount importance. In some circum-
stances additional analyses/tests should be undertaken to
increase conﬁdence in the result. These guidelines should
therefore be used in conjunction with relevant clinical trial
protocols and/or information from the European Leuke-
miaNet (ELN) [7].
Referral can be at diagnosis, follow-up prior to or after
treatment (including transplantation) and at relapse/trans-
formation. Patients may be in or outside a clinical trial. A
close collaboration between genetic laboratories and the
referring clinician/haematopathologist is essential to ensure
that only clinically relevant samples are analysed and that
the most appropriate tests are undertaken. All cytogenomic
analysis or checking should involve at least two-
independent analysts, at least one of whom has appro-
priate experience in haematology cytogenomics. In all
cases, a suitably qualiﬁed person (preferably with profes-
sional registration) must conﬁrm that appropriate investi-
gations have been carried out at an acceptable level of
quality with respect to the referral reason, and authorise the
case report.
Sample type and processing
Choice of sample
For myeloid neoplasms, acute leukaemia and myeloma the
tissue of choice for analysis is bone marrow (BM). BM is
essential for chromosome analysis, it is only appropriate to
use peripheral blood (PB) if there is a signiﬁcant level of
circulating disease [8]. It is advisable to liaise with the
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referring clinician before reporting a normal analysis for this
sample type. For lymphoproliferative disorders such as CLL
the preferred tissue is PB, but BM is an alternative if
inﬁltrated. For FISH analysis, BM or PB smears are an
alternative.
For the majority of lymphomas the most suitable tissue is
lymph node or a relevant biopsy from the primary site.
Analysis of BM or PB analysis is not appropriate unless
there is morphological/immunophenotypic evidence of
inﬁltration.
Sample collection
BM and PB samples are generally taken directly into anti-
coagulant tubes, which must be heparin for cell culture and
EDTA for DNA–based analysis. Alternatively, for chro-
mosome banding analysis, genetic laboratories can provide
clinicians with appropriate transport medium containing an
anti-coagulant as this may reduce the risk of sample failure.
A sufﬁcient quantity of BM (0.5–1 ml minimum) should be
received by the diagnostic laboratory, preferably within 24 h
after aspiration. Ideally the ﬁrst draw should be provided to
avoid haemo-dilution of the sample. Lymph nodes and
other tissues should be supplied in a sterile container with
transport medium. A sufﬁcient quantity of material (5 mm3
minimum) should be received by the diagnostic laboratory,
preferably the same day.
Sample processing
Cell culture Cells should ideally be cultured the day of
reception. If it is unclear whether chromosome band ana-
lysis is required ﬁxed cultured cells can be stored pending
further decisions. Culture choice is dependent on the referral
reason and a range of cell culture techniques must be
available as several factors, such as addition of mitogens or
growth factors and duration of culture, can impact the rate
of detection of an abnormal clone. Therefore at least two
different cultures should be set-up where possible. When
introducing new cultures, laboratories should carry out
appropriate assessments of mitotic indices and abnormality
rates. With the exception of samples that pose a high risk of
infection to laboratory staff, a method for cell counting
should be used to establish an optimum culture density of
1–2 × 106 cells/ml. Detailed protocols can be found in
numerous text books and manuals [9].
One and/or 2 day cultures are standard for all myeloid
disorders. For Myelodysplastic syndromes (MDS) use of
speciﬁc growth factors or conditioned media may improve
quality [10] and cultures with prolonged colcemid exposure
can increase the success rate especially in cases with a low
cell count [11]. For Myeloproliferative neoplasms (MPN),
where BM is not available due to ﬁbrotic marrow, cells
washed from a trephine biopsy can produce a result. It may
be useful to culture both BM and PB for acute leukaemia
(AL) samples as the chromosome resolution of the blasts
may vary. A 48h culture should be considered for cases
where there is suspicion of a t(8;21) or t(15;17) since, in the
experience of many investigators, the aberrant clone is less
reliably detected in the 24h culture.
In vitro cell death can be a signiﬁcant problem for acute
lymphoblastic leukaemia/lymphoma (ALL) samples and
multiple cultures are recommended where practical. Cell
cycle synchronization techniques as well as high colcemid
concentrations or prolonged exposure may have a negative
impact on metaphase yield due to cell poisoning. At
reception, laboratories should consider harvesting one
culture and prepare smears or cell suspensions for
interphase FISH. Additional cultures include overnight
and 2-day cultures, also cultures with addition of growth
factor supplements may be useful [12].
For chronic lymphocytic leukaemia (CLL) analysis of PB
is more successful than BM. The spontaneous proliferation
rate of CLL cells in vitro is low and in order to maximise
the yield of metaphases a 3–5 day culture supplemented
with an oligonucleotide and the cytokine IL2 should be
performed [13–16]. A 3–5 day culture with phorbol 12-
myristate 13-acetate (TPA) may also be useful.
For lymph node specimens 24-h culture is recommended,
additional culture with the addition of mitogens may also be
considered such as 72-h with TPA or addition of an
oligonucleotide and IL2. For other tissues spontaneous
mitoses may be difﬁcult to obtain and addition of mitogens
or growth factors to cultures as described for lymph nodes is
required.
Cell selection procedures For multiple myeloma (MM),
due to the low levels of plasma cells in the BM of some
patients, genetic analysis should be performed on enriched
CD138+ cells or DNA extracted from this cell fraction. PB
should only be considered for plasma cell leukaemia.
Recommended methods of separation include magnetic
bead or ﬂow cytometry but selection can be performed by
any suitable validated technique. The quality of the plasma
cell selection step should be assessed before hybridisation.
Chromosome banding analysis
Chromosome banding analysis is mandatory for several
disease entities (Table 1). Its main advantage is that it
provides whole-genome analysis detecting both numerical
and structural abnormalities and permits the identiﬁcation of
clonal evolution and the presence of multiple independent
clones. However, the requirement for metaphases means
that it is not applicable for all disease entities and the poor
quality of metaphase in some cases means that
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abnormalities may be incorrectly interpreted or remain
unknown. Furthermore some abnormalities are cryptic by
chromosome banding and require complementary testing to
determine their presence.
Expertise in G-banding is assumed throughout this
document, but R- and Q-banding may also be used. It is
essential that the type of banding used is sufﬁcient for the
identiﬁcation of cytogenetically visible recurrent transloca-
tions. Throughout the document, the word ‘score’ is used
with the speciﬁc meaning of checking for the presence or
absence of particular structural or numerical abnormality in
a given number of cells.
As the quality of chromosome morphology and resolu-
tion of neoplastic metaphases is frequently poor, particu-
larly in leukaemia, and requesting repeat samples is often
not an option, no minimum banding quality can be
recommended. Laboratories should be capable of analysing
cells with different resolutions of chromosome banding. As
normal cells with better chromosome morphology may be
present, it is important to analyse cells of varying quality in
order to maximise the likelihood of detecting a neoplastic
clone. Where clariﬁcation of chromosome abnormalities is
required additional testing, such as FISH or microarray
analysis, may be needed.
The ISCN deﬁnition of clonality stipulates that an
identical structural abnormality or chromosome gain should
be present in at least two metaphases while loss of a single
chromosome should be identiﬁed in at least three meta-
phases. For chromosome loss care must be taken to exclude
cells with artefactual random losses in this score. The
ﬁnding of a single abnormal metaphase necessitates further
screening or testing by another technique to determine
clonality, particularly a single cell with trisomy 8 or
monosomy chromosome 7 in myeloid neoplasms.
Polyploid and hypodiploid/apparently broken meta-
phases should not be excluded from the analysis, although
cells with loss of >6 chromosomes cannot be considered to
be fully analysed unless the loss is part of the clonal change.
Laboratories should be aware that co-existing clones and
clonal evolution may be present and additional analysis
should be undertaken if suspected. Analysis from more than
one culture regimen should be considered if no abnormal
clone is detected, particularly where the lineage of the
neoplastic cells is uncertain.
Analysis at diagnosis
When no abnormality is found in a diagnostic sample a
minimum of 20 metaphases must be examined. This will
exclude the presence of a chromosomally abnormal clone of
14% with 95% conﬁdence [17]. Ten metaphases should be
fully analysed, with a further ten analysed or counted and
scored for relevant structurally abnormal chromosomes. If a
normal result is based on examination of fewer than 20
cells, the report must be suitably qualiﬁed stating that the
analysis cannot reliably exclude a signiﬁcant clonal
abnormality.
When a clonal abnormality is found at diagnosis a
minimum of ten metaphases must be analysed, where pos-
sible. Where a constitutional chromosome abnormality is
suspected, screening additional metaphases may permit the
detection of a normal cell line. If a constitutional origin
cannot be excluded, analysis of a phytohemagglutinin
(PHA) stimulated PB sample may be requested. Con-
sideration should be given to the wider implications for the
patient and their family members.
Follow-up after treatment or in remission
Where cytogenetic follow-up is required, the following
strategies are recommended:
● Normal result obtained at diagnosis: further analysis is
usually not appropriate.
● Abnormal result obtained at diagnosis: chromosome
analysis is appropriate. Normal result obtained: Mini-
mum of 20 metaphases should be analysed or scored for
the diagnostic abnormality. Abnormal clone detected:
Minimum analysis can be limited to 10 metaphases.
● Where cells were only scored, the report should qualify
that the analysis only excludes the presence of that
speciﬁc abnormality.
● Where possible, for follow-up studies/detection of
minimal residual disease, quantitative polymerase
chain reaction (RQ-PCR), other molecular technologies
as well as multi-parametric ﬂow cytometry are
preferable.
● For post-transplantation samples molecular technologies
are preferable. FISH can be used if a suitable marker
was identiﬁed at diagnosis.
For samples at possible relapse or transformation or
secondary haematological neoplasm
If clinical information is suggestive of relapse, refractory
disease or a second haematological neoplasm, repeat ana-
lyses are indicated and samples should be processed as
described for diagnostic samples.
Interphase and metaphase ﬂuorescent in situ
hybridisation (FISH)
Interphase FISH, with an appropriate panel of probes, may
be used as a sole or ﬁrst line test for some neoplasms
(Table 1). FISH analysis is useful for neoplasms where
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metaphases are difﬁcult to obtain and where rapid diag-
nostic testing is required for therapeutic decision making.
FISH is the method of choice where the abnormality is not
amenable to other molecular methods due to variable
breakpoints (for example IGH), where rearrangement of
speciﬁc genes involves multiple possible partner genes (for
example KMT2A), where the abnormality is sub-
microscopic (microdeletions) or cryptic by chromosome
banding analysis. For deletions laboratories should consider
the size range of the critical deleted region to ensure that the
FISH probe is capable of reliable detection. Very small
copy number changes should be tested by array or other
molecular methods. FISH analysis is a useful com-
plementary technique, particularly in combination with
array data (Table 1) for the detection of balanced rearran-
gements, and to clarify chromosome banding analysis.
Locus-speciﬁc FISH should be considered to conﬁrm or
exclude chromosome rearrangements with prognostic
implications if their presence is in doubt. The disadvantage
of FISH is that it is a targeted analysis and therefore needs
to be combined with other testing to provide comprehensive
information of chromosome abnormalities.
Any FISH system used in a diagnostic setting must be
validated. Thresholds and conﬁdence limits should be
established for all FISH probes and probe sets. Validation
should include documentation of aberrant signal patterns for
a number of normal and abnormal samples to establish the
false positive/negative ranges. It is important to establish the
thresholds/conﬁdence limits using a variety of different
preparations which reﬂect the typical diagnostic samples
(e.g. ﬁxed cells, smears, cytospins, parafﬁn embedded
sections, touch preparations etc.). When applicable, ade-
quate control probes should be included in the hybridisa-
tion. Laboratories must be aware of the different types of
FISH probes and have documentation available that
explains normal and abnormal signal patterns e.g. dual
colour break apart probes and dual colour dual fusion
probes. There are many publications and text books which
provide detailed methodology, expected signal patterns and
examples of applications [18].
A minimum analysis of 100 interphase nuclei is recom-
mended for diagnostic samples. For follow-up of previously
detected clonal anomalies at least 200 interphase nuclei
must be analysed. For minimal residual disease with
recurrent rearrangements, RQ-PCR or other molecular
technologies are more appropriate. It is recognised that an
adequate-positive result can often be obtained from a
smaller number of cells. An equivocal ﬁnding (i.e. the
possibility of a low-level clone close to the threshold cutoff)
may need more cells and/or a repeat investigation. Care
should be taken when reporting these equivocal ﬁndings to
avoid over interpretation. When results are just above the
cutoff value, the report should state that the clinical
signiﬁcance is unclear. It can be useful to examine meta-
phases, if present, as analysis of normal metaphases con-
ﬁrms cytogenetic location of the probes used and abnormal
metaphases can be invaluable in interpreting unusual signal
patterns.
The use of FISH on formalin ﬁxed parafﬁn embedded
(FFPE) sections or touch preparations/smears is an appro-
priate approach for investigation of speciﬁc chromosomal
aberrations and has the advantage that tumour tissue can be
directly screened [19–21]. When analysing FFPE sections it
is important to analyse areas of the tissue containing the
tumour cells and not to limit the analysis to one area of the
section. Since lymphoma often has a diffuse pattern of
inﬁltration, identiﬁcation of speciﬁc areas of tissue con-
taining the tumour cells prior to analysis is not
always required, unless the lymphoma is in situ/focal or
there is necrosis present. It should be noted that a high
number of T cells and other normal/reactive cells may be
present.
The number of cells for analysis of FFPE specimens will
vary on a case by case basis; the focus should be on
determining the presence or absence of a rearrangement not
on speciﬁc numbers of cells analysed. Although it is
optional to include the number of cells analysed in the
report, if reported, it should speciﬁcally represent the
number of tumour cells analysed. At analysis, care should
be taken to note any areas of differential digestion, as
tumour cells can be over- or under-digested compared to
normal cells, and optimum quality of hybridisation should
always be sought. If sub-optimum hybridisation has
occurred, repeat deparafﬁnation/FISH is recommended with
additional optimisation of the pre-treatment prior to FISH.
A common limitation of FFPE FISH is that there may be a
large proportion of cells displaying one (or no) signal,
consistent with signal dropout (truncation of cell nucleus),
and should not be reported. Due to variable signal dropout,
and variation in the size of cells, analysis for speciﬁc
deletions using FFPE tissue needs to be carefully con-
sidered and appropriate probe design with controls is
essential. It is important not to over-interpret apparent signal
loss as actual deletion of the probe or the presence of an
unbalanced translocation.
Genomic arrays
To overcome some of the limitations of chromosome
banding analysis and targeted FISH, genome wide screen-
ing for the detection of copy number abnormalities (CNA)
and acquired copy neutral loss of heterozygosity (aCN-
LOH) using microarrays was introduced. This technology
can be used as a complementary test or, depending on the
neoplasia investigated, as a standalone test. It can be used at
diagnosis and follow-up but is not suitable for minimal
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(measurable) residual disease (MRD) monitoring after
treatment (including transplantation).
As no cell culture is required and clone selection due to
cell proliferation is avoided it is a valuable technique for
pathologies where chromosome banding studies are difﬁcult
or impossible to perform, where there are no or insufﬁcient
metaphases, where a normal karyotype and normal FISH
results are obtained at diagnosis and where chromosome
resolution is poor. Arrays are particularly useful for neo-
plasms where multiple CNAs are tested, replacing multiple
FISH analyses, and is increasingly important for the
detection of very small CNAs. However, it is important to
note that one of the limitations of microarrays is that they
cannot exclude some recurrent translocations and so addi-
tional testing is required for some diseases.
Microarray analysis allows accurate detection of a
number of very small CNAs of prognostic signiﬁcance and
can identiﬁy genomic instability, including complex geno-
mic aberrations such as chromothripsis. Microarrays con-
taining single nucleotide polymorphisms (SNPs) enables
ploidy level to be established and allows the detection of
aCN-LOH. These regions often mask point mutations in
tumour suppressor genes and therefore serve as important
indicators for further molecular investigations such as Next
Generation Sequencing (NGS).
It is essential that the sensitivity and resolution of
genomic regions harbouring clinically relevant genes are
established by a thorough internal validation of known
abnormal samples prior to diagnostic use. Speciﬁc
guidelines for genomic array analysis in acquired haema-
tological neoplastic disorders were published in 2016 [22].
Testing strategies
Each haematological neoplasm is deﬁned by a spectrum
of genetic aberrations of diagnostic and/or prognostic
signiﬁcance and the testing required is pathology spe-
ciﬁc. Essential testing is discussed within the speciﬁc
disease sections and summarised in Table 1. Recom-
mended testing can be achieved by different (or com-
bined) technological approaches (Table 2) and analytical
strategies will vary depending on local policy and
infrastructure. It is recognised that testing is a rapidly
evolving ﬁeld and that the introduction of new technol-
ogies will vary between laboratories and from country to
country. There are now methods which can simulta-
neously detect numerical and structural abnormalities as
well as mutations in one assay [23]. While this approach
has not yet been introduced extensively into routine
testing, it is acknowledged that this may change in the
future and therefore this has been included as an alter-
native strategy in Table 2.
Disease-speciﬁc recommendations
In this section we provide the recommended disease-speciﬁc
cytogenomic testing required. This section includes:
Table 2 Alternative testing strategies
Testing requirement Alternative strategies for testing
Whole-genome numerical and structural abnormalities Chromosome banding plus FISH/molecular testing for recurrent cryptic
structural abnormalities
or
Array/NGS copy number analysis plus FISH/molecular analysis for
recurrent structural abnormalities
or
Whole-genome NGS analysis including copy number and structural
abnormalities
Targeted region-speciﬁc analysis for recurrent structural
abnormalities deletions, gain, translocations
FISH for copy number and structural abnormalities
or
FISH for copy number plus molecular techniques for structural
abnormalities
or
Molecular-based copy number (e.g. MLPA, PCR) plus FISH/molecular
analysis for recurrent structural abnormalities
or
Targeted Array/NGS copy number analysis plus FISH/molecular analysis
for structural abnormalities
or
Targeted NGS analysis, including copy number and structural abnormalities
NGS next generation sequencing
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● Chronic myeloid leukaemia (CML) at diagnosis and
follow-up for staging purposes or to monitor therapy
efﬁcacy.
● Chronic myeloproliferative neoplasms (MPN) for
selected cases or where there is acute leukaemic
transformation.
● Myeloid/lymphoid neoplasms with eosinophilia at
diagnosis.
● Myelodysplastic syndrome (MDS) at diagnosis, at
disease progression and after treatment.
● MDS/MPN and germ line predisposition.
● Acute leukaemia at diagnosis and follow-up.
● Chronic lymphocytic leukaemia (CLL) for prognostica-
tion at time of treatment and/or clinical progression or to
aid in differential diagnosis.
● Multiple myeloma for prognostication.
● Lymphoma and other lymphoproliferative disorders
(LPD) in selected cases at diagnosis, follow-up or
relapse and to aid in differential diagnosis or
prognostication.
In a proportion of cases the diagnosis is not known at
referral. Some testing, such as chromosome banding ana-
lysis and any rapid testing requested, needs to be initiated at
sample reception and thus, in the absence of any further
clinical information, sufﬁcient testing should be undertaken
taking into account the different diagnoses possible. Fixed
cell cultures can be stored for analysis pending further
information. Other testing such as non-urgent FISH or
molecular testing can be initiated once more information is
available.
Chronic myeloid leukaemia (CML)
The t(9;22)(q34;q11) is the hallmark of CML and results in
the generation of the Philadelphia chromosome (Ph), der
(22)t(9;22)(q34;q11). This translocation is detected in
90–95% of CML cases at diagnosis. The remaining 5–10%
have a variant t(9;22) involving additional chromosomes or
have a cryptic rearrangement, usually an insertion, resulting
in the presence of a BCR-ABL1 gene fusion.
In some patients additional chromosome abnormalities
(ACA) in Ph positive (Ph+) cells are present at diagnosis. It
is important to detect these as they may identify patients at
risk of disease acceleration [24–27] and aid the interpreta-
tion of results from subsequent samples. ACA can be
deﬁned as ‘major route’ abnormalities or ‘minor route’
abnormalities [27, 28]. Abnormalities in Ph+ cells, arising
during the course of the disease (clonal evolution), are an
independent poor prognostic factor for survival in both
chronic and accelerated phases (AP) of CML [29, 30].
WHO 2017 classiﬁcation deﬁnes new criteria for AP that
includes the presence of speciﬁc ACA [1]. Major route
abnormalities (a second Ph chromosome, trisomy 8, iso-
chromosome 17q, trisomy 19), complex karyotype and
abnormalities of 3q26.2 are each criterion for accelerated
phase as is the appearance of any new clonal chromosomal
abnormality in Ph+ cells that occurs during therapy.
The ELN recommendations for analysis of CML should
be followed [24, 25]. Chromosome analysis is mandatory
for CML at diagnosis. It is strongly recommended that 20
cells are fully analysed to exclude the presence of ACA. If a
variant translocation is detected then BCR-ABL1 fusion
must be conﬁrmed by FISH or reverse transcription PCR
(RT-PCR). A rapid preliminary test may be undertaken with
BCR/ABL1 FISH probe using a direct harvest or smears. It
is recommended that dual fusion probes are used as they
give a more reliable informative signal pattern than the ES
(extra signal) probe. FISH is mandatory for cases with an
insufﬁcient number of metaphases and for cases with a
normal karyotype, to exclude a cryptic abnormality. If no
BCR-ABL1 fusion can be detected by FISH, and CML is
still clinically suspected, then RT-PCR and/or molecular
testing for mutations associated with other myeloprolifera-
tive neoplasms (MPN) is required (see MPN section below).
Response to treatment can be determined cytogenetically
by monitoring the reduction in the number of Ph+ cells.
Follow-up chromosome analysis should be performed at 3,
6 and 12 months post treatment until a complete cytogenetic
response (CCyR) has been achieved and at least 20 cells
must be fully analysed for disease monitoring [25]. More
frequent monitoring may be required for patients in whom
additional abnormalities were found at diagnosis as these
may have an adverse response to TKI therapy [24]. If a
cryptic BCR-ABL1 rearrangement was detected at diagnosis
then follow-up must be done by FISH or molecular meth-
ods. Once CCyR has been achieved chromosome analysis
can be replaced by FISH. Accurate interpretation of FISH
follow-up requires prior knowledge of the signal pattern at
diagnosis, and cases with only a single fusion signal cannot
reliably be monitored by FISH [25]. If RQ-PCR metho-
dology is standardised, and expressed according to the
International Scale, then response can be assessed using
only RQ-PCR [25]. For follow-up, peripheral blood sam-
ples are more appropriate for the subsequent study of
response to treatment.
Although the purpose of genetic analysis after therapy is
to monitor the level of Ph+ cells, it is also recognised
that new clonal abnormalities are occasionally detected in
Ph− cells and these should be followed up in subsequent
samples. Whilst unexpected additional abnormalities may
be transient and of no clinical signiﬁcance [24, 31], a
minority (2–10%) of these CML patients go on to develop
clinically evident MDS/AML, a risk associated particularly
with Ph− clones harbouring deletions of 7q or monosomy
7 [24].
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Myeloproliferative neoplasms (MPN)
MPN is a heterogeneous group of disorders characterised by
proliferation of one or more myeloid lineages. The WHO
classiﬁcation of MPN includes CML (covered in the pre-
vious section), chronic neutrophilic leukaemia (CNL),
polycythaemia vera (PV), primary myeloﬁbrosis (PMF),
essential thrombocythaemia (ET), chronic eosinophilic
leukaemia NOS and mastocytosis.
For many referrals of MPN, the differential diagnosis is
CML and the important genetic requirement is exclusion of
the BCR-ABL1 rearrangement. Mutation analysis of JAK2,
CALR and MPL is particularly important in the diagnostic
workup of some MPN [1, 32, 33]. Currently these mutations
are considered diagnostic, but may, in time, inﬂuence
treatment decisions and prognosis. Cytogenetic studies are
not essential and many laboratories do not offer chromo-
some analysis because of this lack of speciﬁcity. However,
recently the karyotype has been included in the DIPSSPlus
prognostic scoring systems in primary PMF [34–38] and it
has been suggested that it may also be a useful indicator in
PMF post PV or ET [39].
Myeloid/lymphoid neoplasms with eosinophilia and
abnormalities of PDGFRA, PDGFRB and FGFR1 or
with PCM1-JAK2
A distinct classiﬁcation of myeloid and lymphoid neo-
plasms associated with eosinophilia and rearrangements of
PDGFRA, PDGFRB, FGFR1 or with a PCM1-JAK2 rear-
rangement is described in the WHO 2017 [1]. This disorder
is associated with recurrent rearrangements which have
variable responsiveness to targeted drugs. FIP1L1-
PDGFRA, PCM1-JAK2 gene fusions and PDGFRB and
FGFR1 and PCM1-JAK2 gene rearrangements should be
excluded by FISH or RT-PCR [40]. Since almost all tyr-
osine kinase gene fusions, apart from FIP1L1-PDGFRA, are
associated with visible chromosome rearrangements chro-
mosome banding studies may be performed for screening.
Myelodysplastic syndromes (MDS)
Cytogenetic analysis of bone marrow aspirate should be
performed in all patients with suspected MDS for whom
bone marrow examination is indicated [41]. Selected
recurrent abnormalities are recognised as presumptive evi-
dence of MDS, even in the absence of deﬁnitive morpho-
logic features [1]. The cytogenetic risk group is included in
the IPSS-R prognostic scoring system [42, 43]. Although
this is based on chromosome analysis, abnormalities
detected by FISH or array may provide prognostic
information.
SNP-array is emerging as an important tool in MDS.
aCN-LOH as a sole genomic abnormality is a recurrent
ﬁnding in MDS with normal karyotypes and these regions
often harbour point mutations in genes associated with poor
outcome in MDS such as ASXL1, EZH2, TP53 and RUNX1.
Mutation screening with NGS panels is therefore strongly
recommended in cases with aCN-LOH and a good IPSS-R
score.
If no, or insufﬁcient, metaphases are obtained, array or
FISH analysis for monosomy 5/deletion of 5q and monos-
omy 7/deletion 7q, must be undertaken. Analysis can be
extended to include trisomy 8, TP53 deletion and 20q
deletion [41]. Where morphology or immunophenotype
suggests a deletion of 5q or MECOM gene rearrangement
(poor risk according to IPSS-R), in the absence of cytoge-
netic abnormality, further testing must be undertaken. Point
mutations in the TP53 gene have been reported to cause
resistance to lenalidomide in 5q deletion MDS patients.
Therefore mutation analysis of TP53 is indicated in patients
with low or absent treatment response, or should be
recommended in the report if not performed in the
laboratory.
Patients with aplastic anaemia (AA) may be referred to
rule out MDS. AA results from bone marrow failure and is
not a neoplastic disorder. Consideration should be given to
the possibility of Fanconi anaemia, especially in childhood
aplastic anaemia and liaison with the referring clinician with
regard to appropriate testing is important. SNP array can be
used as a complementary test to detect recurrent abnorm-
alities observed in AA that will not be detected by chro-
mosome banding analysis, such as aCN-LOH for 6p. aCN-
LOH 6p is not a clonal abnormality related to neoplasia but
is thought to arise as an escape mechanism in this auto-
immune disorder [44].
Myelodysplastic/myeloproliferative neoplasms
This category includes myeloid neoplasms with overlapping
features of MDS and MPN and encompasses chronic
myelomonocytic leukaemia (CMML), atypical CML
(aCML), juvenile myelomonocytic leukaemia (JMML), and
MDS/MPN with ring sideroblasts and thrombocytosis
(MDS/MPN-RS-T) [1]. Some of these diseases are char-
acterized by mutations in certain genes like SF3B1 in MDS/
MPN-RS-T. Chromosome banding analysis of referrals
within the MDS/MPN classiﬁcation group can be con-
sidered within the same category as MDS referrals. How-
ever, it is important to note that the revised International
Prognostic Scoring System (IPSS-R) [42] does not apply to
this pathology. For CMML, a CMML-speciﬁc prognostic
scoring system integrating cytogenetics has been proposed
[45].
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Myeloid neoplasms with germ line predisposition
A subgroup of MDS, MDS/MPN and acute leukaemia cases
are associated with a familial predisposing germ line
mutation (e.g. DDX41, CEBPA, GATA2, TP53 and genes
involved in bone marrow failure syndromes and telomere
biology disorders – see Table 7.03 WHO 2017) [1] and
analysis should be performed where appropriate.
There are two constitutional chromosome abnormalities
associated with predisposition to myeloid neoplasm, tris-
omy 21 Down syndrome and rare Robertsonian rob(15;21)
(q10;q10) or der(15;21)(q10;q10). Patients with Down
syndrome are at a higher risk of developing leukaemia in
childhood (AML and ALL) - this also includes transient
abnormal myelopoiesis (TAM). An additional copy of
chromosome 21 is a rare but recurrent ﬁnding in myeloid
neoplasia and therefore the ﬁnding of trisomy 21 in all cells
should prompt a check regarding patient phenotype if
unknown. Patients with rob(15;21) are at an increased risk
(>2000-fold) of ALL with iAMP21 [46].
Acute myeloid leukaemia (AML)
Several AML disease entities are deﬁned by the presence of
speciﬁc cytogenetic and molecular genetic abnormalities
[1]. Chromosome analysis is mandatory at diagnosis for risk
stratiﬁcation [41]. Diagnostic workup should also include
screening for molecular mutations in genes such as NPM1,
FLT3, CEPBA, RUNX1, ASXL1, DNMT3A, and TP53 and is
especially important in AML with normal karyotype
where these ﬁndings can deﬁne the subtype of the disease
[1, 47–49]. FISH or molecular techniques may be required
if a rapid result is required.
FISH analysis of interphase nuclei and metaphases to
screen for KMT2A and MECOM gene rearrangements is
recommended for all diagnostic AML samples if no other
entity deﬁning cytogenetic or molecular genetic abnorm-
ality is present, as these abnormalities may be cryptic and
have a pronounced prognostic impact. Where karyotype has
failed, or the presence of a speciﬁc abnormality is suspected
clinically or morphologically but was not conﬁrmed by
cytogenetic analysis, additional FISH or molecular analysis
is recommended for PML-RARA, CBFB-MYH11 or
RUNX1-RUNX1T1 rearrangements. In very rare cases all
three techniques may be required as the gene rearrangement
may be cryptic by more than one of these approaches. For
karyotype failure monosomy 5/del(5)(q31.2) and monos-
omy 7/del(7)(q31.2), should also be excluded. FISH may
also be used where abnormalities recurrently associated
with speciﬁc rearrangements are found e.g. association of
inv(16) with trisomy 22. FISH testing for the cryptic t(5;11)
(q35.2;p15.4);NUP98-NSD1 should be carried out in
patients <5 years old with a normal karyotype due to the
poor prognostic association [50–52]. Other abnormalities
have been identiﬁed in paediatric AML which may require
routine testing in the future: t(7;12)(q36;p13);MNX1-ETV6
occurs mainly in infants, often accompanied by a deletion
7q [53, 54] and trisomy 19, and inv(16)(p13.3q24.3);
CBFA2T3-GLIS2 [55, 56].
Acute lymphoblastic leukaemia/lymphoma (ALL)
WHO 2017 and other publications [57–60] provide an
overview of the non-random abnormalities found in
B-lymphoblastic leukaemia/lymphoma. The most sig-
niﬁcant genetic diagnostic and prognostic factors for adult
and paediatric B-ALL are: t(9;22)(q34;q11.2);BCR-ABL1;
t(v11q23);KMT2A (MLL) rearrangements; t(12;21)(p13;
q22);ETV6-RUNX1; high hyperdiploidy; near haploidy; low
hypodiploidy; t(1;19)(q23;p13.3);TCF3-PBX1; intrachro-
mosomal ampliﬁcation of chromosome 21 (iAMP21) and t
(17;19)(q22;p13.3);TCF3-HLF. There is also a unique
association between low hypodiploid ALL and TP53
mutations which are often constitutional [61].
Screening for recurrent fusion genes by FISH/RT-PCR
and chromosome banding analysis remain the gold stan-
dard methods for clinical diagnosis in BCP-ALL [57] and
rapid diagnosis of clinically relevant recurrent abnormal-
ities by FISH or RT-PCR should be undertaken. For B-
ALL it is recommended that BCR-ABL1, ETV6-RUNX1
and KMT2A gene rearrangements are routinely tested
depending on the age of the patient (Table 3). This
combination of probes allows the identiﬁcation of other
recurrent abnormalities e.g. iAMP21. Rapid diagnostic
tests may be run simultaneously or sequentially (Table 3).
When a TCF3 break apart probe detects a rearrangement,
Table 3 Recommended analyses
for fusion gene rearrangement
testing in ALL
Patient details Recommended Optional
B-ALL Infants (<1 year old) KMT2A ETV6-RUNX1, BCR-ABL1
For paediatric/adolescent
ALL (<25 years)
ETV6-RUNX1, BCR-ABL1, then
KMT2A and TCF3
Adult BCR-ABL1 then KMT2A and TCF3 ETV6-RUNX1
T-ALL Childhood and adult TLX3, TLX1, KMT2A, TAL1,
LMO2 and ABL1
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it is important to distinguish between a t(17;19) and a
t(1;19) as the prognosis is different. Additional FISH
testing should be considered for potential high-
hyperdiploidy if the karyotype is normal or is unsuc-
cessful e.g. 4, 10, 17 and 18 [62]. For clinical trial cases it
may be necessary to do further FISH analysis. A targeted
FISH approach has been proposed which detects the most
signiﬁcant chromosomal abnormalities. Using this
approach, depending on the abnormality detected, it is not
necessary to carry out full banded analysis in all cases of
childhood B-cell precursor ALL [57].
In cases where extra RUNX1 signals are found, intra-
chromosomal ampliﬁcation of chromosome 21 (iAMP21) is
deﬁned as 5 or more copies present in interphase nuclei (or
3 or more extra copies on as single abnormal chromosome
21 in metaphase FISH) with clustering of signals (although
individual cells may display apparently distinct signals).
Where extra RUNX1 signals are not obviously clustered
these are more likely to be indicative of a hyperdiploid
karyotype. A hyperdiploid karyotype with more than 50
chromosomes will rarely display more than four RUNX1
signals.
B-ALL classiﬁcation includes the provisional entity B-
lymphoblastic leukaemia/lymphoma, BCR-ABL1–like.
BCR-ABL1–like ALL cases contain a variety of genomic
alterations that activate kinase and cytokine receptor sig-
nalling pathways. These alterations can be grouped into
major subclasses that include ABL-class fusions involving
ABL1, ABL2, CSF1R, and PDGFRB that phenocopy BCR-
ABL1 and alterations of CRLF2, JAK2 and EPOR that
activate JAK/STAT signalling. This disease entity is
assuming increasing importance because of its association
with an adverse prognosis and response to targeted
therapies. Patients with ABL-class fusions respond clinically
to ABL1 tyrosine-kinase inhibitors, whereas mutations
activating the JAK/STAT pathway are amenable to
treatment with JAK inhibitors in vitro or in preclinical
models [63].
Near-haploid or low hypodiploidy is associated with a
poor prognosis whereas hyperdiploidy is associated with a
favourable prognosis. Near-haploid or low hypodiploid
clones can ‘double-up’ and appear as hyperdiploid/near-
triploid metaphases and it is therefore important to dis-
tinguish these cases from true hyperdiploid cases.
Hyperdiploid clones originate from simple gain of chro-
mosomes in a diploid cell line. Near haploid
or low hypodiploid clone can easily be identiﬁed by SNP-
array due to the presence of multiple whole chromosome
CN-LOH.
For T-ALL, an abnormal karyotype is reported in
50–70% of cases [1]. Numerical abnormalities are less
frequently observed than in B-ALL with the exception of
tetraploidy, which is present in ~5% of cases. Around 35%
of T-ALL have rearrangements involving the TCR loci at
7q34 (TRB) or 14q11.2 (TRA/TRD) [64, 65]. TLX3 and
TLX1 abnormalities are observed in 25% and 5% of child-
hood T-ALL patients, respectively. The NUP214-ABL1
fusion gene is found ampliﬁed as multiple (5–50) episomal
copies in 6% of cases.
FISH for T-ALL is optional but could include TLX3,
TLX1, KMT2A, TAL1, LMO2 and ABL1 rearrangements.
FISH for BCR-ABL1 (Table 3) can be used to determine the
presence of the BCR-ABL1 fusion, but also for the detection
of ABL1 ampliﬁcation. Ampliﬁcation of ABL1 is indicative
for the presence of NUP214-ABL1 episomes. The presence
or absence of ABL1 ampliﬁcation should be stated in the
report, as this might inﬂuence treatment decisions in T-ALL
[66, 67].
Many ALL cases are characterised by the presence of
distinct sub-microscopic DNA copy number alterations,
several of which are of clear clinical importance for risk
stratiﬁcation [68–70]. Array analysis is now being incor-
porated into clinical trials and may ultimately be introduced
into routine practice. It is therefore strongly recommended
that laboratories perform array analysis of all new diag-
nostic ALL cases.
Chronic lymphocytic leukaemia/small lymphocytic
lymphoma
Chromosomal abnormalities in chronic lymphocytic leu-
kaemia (CLL) are detected in up to 80% of patients. The
most signiﬁcant genetic diagnostic and prognostic factors
are deletions of 11q, 13q, 17p and trisomy 12 [71]. IWCLL
guidelines [71] recommend screening for these abnormal-
ities for pre-treatment evaluation and prognostic stratiﬁca-
tion. Suitable methodologies include FISH, array and other
molecular methods. Although chromosome banding analy-
sis has been improved with the use of oligonucleotide and
IL2 it should not be considered as a standalone test as very
small 13q14 deletions are frequent and cannot be identiﬁed
by karyotyping. Patients showing TP53 deletion and/or
mutation are refractory to standard chemo-immunotherapy
regimens [72–74]. In accordance with the European
Research Initiative on CLL (ERIC) recommendations, TP53
should be screened for deletions and point mutations prior
to treatment [75]. Determination of IGHV mutational status
is also mandatory [76]. Complex karyotypes with three or
more abnormalities and some recurrent mutations have been
reported to have a prognostic signiﬁcance in CLL. Although
more prospective trial data is required before it can be
recommended for clinical practice [71] this testing may be
included in future recommendations [77–81]. For cases of
CLL with a differential diagnosis of mantle cell lymphoma
(MCL) FISH to exclude a t(11;14)(q13;q32) should be
performed.
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Multiple myeloma
Multiple myeloma (MM) is a neoplastic disorder char-
acterised by a monoclonal proliferation of plasma cells in
the bone marrow (or tissue) with associated acquired
genetic abnormalities of clinical importance [1]. The genetic
picture is frequently complex and there can be high intra-
clonal variability.
The International Myeloma Working Group [82] and
the European myeloma network [83] state that the
minimum testing required is determination of TP53 deletion
and presence of a t(4;14)(p16;q32); FGFR3/MMSET-
IGH gene rearrangement. Testing for t(14;16)(q32;q23);
MAF-IGH gene rearrangement is also recommended
[80–82]. Testing for FGFR3-IGH and MAF-IGH rearran-
gement can be excluded either by use of an IGH break apart
probe, as a ﬁrst line test, or by use of both FGFR3/IGH and
MAF/IGH dual fusion probes. If an abnormal pattern is
detected using an IGH break apart probe as a ﬁrst line test,
then further testing fort (4;14)(p16;q32);FGFR3/MMSET-
IGH, and t(14;16)(q32;q23);MAF-IGH is required. If a
single IGH dual fusion translocation probe is used as a ﬁrst
line test it is important to note that a normal result does not
conclusively exclude the presence of any other IGH rear-
rangement if, for example, monosomy 14 or deletion 14q32
is present. Therefore, sufﬁcient testing should be performed
to exclude these rarer possibilities.
Other groups have included testing for 1q gain in their
prognostic models [83, 84] and consequently some
national guidelines have included this additional test in
their recommendations [85]. 1p/1q testing is now being
incorporated into clinical trials and may ultimately
become an essential test. It is therefore strongly recom-
mended that laboratories include this in their
testing strategy. An extended panel may include testing
for t(11;14)(q13;q32);CCND1-IGH, t(14;20)(q32;q12);
MAFB-IGH, MYC translocations and ploidy status (if not
evaluated with DNA index content) [82, 86]. When
assessing hyperdiploidy by FISH the presence of any two
chromosomes from a panel including 5, 9 and 15 can be
considered a highly speciﬁc indicator [86]. In this rapidly
changing ﬁeld it is essential that laboratories keep up to
date with any new recommendations for minimal essential
tests. To limit the large number of FISH tests performed,
MLPA or arrays can be used to assess copy number
changes but FISH testing is required for IGH translocation
status.
When analysing FISH, at least 100 selected plasma cells
(PC) should be scored. The quality of the PC selection step
should be assessed before hybridisation. In the absence of a
reliable method of identifying and selecting PCs, a totally
normal result must be qualiﬁed, highlighting the possibility
of a false-negative result. Positive cutoff levels should be
relatively conservative: 10% for fusion or break apart
probes, 20% for numerical abnormalities [87].
Other LPDs
There are no disease-speciﬁc chromosome abnormalities
associated with Hairy cell leukaemia or Waldenstrom
macroglobulinaemia/lymphoplasmocytic lymphoma and
therefore chromosome banding analysis is not required.
Mutation screening should be undertaken for these entities
[1].
B-cell lymphomas
Several recurrent cytogenetic and molecular genetic
abnormalities have been described in lymphoma [1].
Genetic testing is not generally performed routinely for all
lymphoma cases and is usually restricted to cases with a
differential diagnosis or for prognostication purposes. Many
abnormalities are not speciﬁc to a particular disease and so
the result needs to be integrated with the histological
reports, immunophenotype and any other genetic abnorm-
alities. Guidelines on the diagnosis and reporting of lym-
phoproliferative disorders (LPD) and Lymphoma have been
published that also give valuable recommendations for all
laboratories/MDTs [88].
The most common recurrent chromosome abnormalities
which can aid in differential diagnosis are given below. A
comprehensive list can be found in WHO, 2017 or Heim &
Mitelman, 2015. [1, 65]
● Mantle cell lymphoma: t(11;14);CCND1-IGH, and IGK/
IGL and CCND2&3 variants.
● Follicular lymphoma: t(14;18); BCL2-IGH, and IGK/
IGL variants, and less frequently BCL6 rearrangements,
● Diffuse large B-cell lymphoma (DLBCL): IGH (50%),
BCL6 (30%), BCL2(20–30%) and MYC (10%) gene
rearrangements.
● ALK-positive DLBCL: t(2;17)(p23;q23);CLTC-ALK or
rarely other translocations including t(2;5)(p23;q35);
NPM1-ALK translocation.
● Burkitt lymphoma: t(8;14);MYC-IGH, and IGK/IGL
variants, with no additional involvement of BCL2 or
BCL6 or complex karyotype.
● Burkitt-like lymphoma with 11q aberration: charac-
terised by chromosome 11q proximal gains and
telomeric losses and no MYC rearrangement.
● Extra nodal marginal zone lymphoma of mucosa-
associated lymphoid tissue: t(11;18)(q21;q21); BIRC3-
MALT1; t(1;14)(p22;q32);BCL10-IGH; t(14;18)(q32;
q21);MALT-IGH and t(3;14)(p14.1;q32);FOXP1-IGH,
trisomy 3 and/or trisomy 18. It should be noted that the
t(14;18); MALT1-IGH translocation is cytogenetically
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identical to the t(14;18); BCL2-IGH translocation and
that FISH is required to distinguish between them in
cases with a differential diagnosis.
● T-cell prolymphocytic leukaemia: 14q11 (TRA/D)
rearrangement in 80–90% T-PLL.
● Anaplastic large cell lymphoma (ALCL): ALK gene
rearrangement, most frequent t(2;5)(p23;q35);ALK-
NPM1.
● ALK-negative ALCL: DUSP22-IRF4 rearrangement,
most commonly a t(6;7)(p25.3;q32.3) or TP63
rearrangements.
For prognostication, the most common referral is to
exclude MYC rearrangement in the context of DLBCL or
High grade B-cell lymphomas. High-grade B-cell lym-
phoma, with MYC and BCL2 and/or BCL6 translocations
(so called “double-hit” or “triple-hit” lymphomas in the
WHO 2008 [89]) often show complex karyotypes. For this
disease entity FISH testing with IGH, BCL2 and BCL6
probes is essential for correct disease classiﬁcation. The
ﬁnal classiﬁcation should be combined with histology.
There is no consensus or speciﬁc guidelines on when to
undertake genetic testing of DLBCL. Some believe that all
DLBCL should be tested for MYC, BCL2 and BCL6 rear-
rangements, whereas others would restrict this, to cases with
a GCB phenotype and/or high-grade morphology or to
cases with >40% MYC-positive cells by immunophenotype
[1].
Reporting
Reports of cytogenomic analyses should comply with
ISO15189 standards and include the following information
[90].
● Two unique patient identiﬁers (e.g. date of birth, full
name—not initials);
● Sample information (type and source of sample, date of
sample referral, date of report and unique sample
identiﬁcation);
● Referral information (reason for referral and clinical
indication for test);
● Referring physician/scientist identiﬁcation;
● Names of signiﬁcant genes at loci involved in any
established recurrent rearrangement;
● Gene names must be written following HUGO gene
nomenclature (http://www.genenames.org);
● When there is fusion or rearrangement, the genes should
be written as BCR-ABL1 (i.e. use a – sign rather than a /)
to distinguish the fusion product from a mixed probe kit;
● Long reports should be avoided as this detracts from the
clarity of the results. Methodology and limitations of the
test should not take prominence in a report as they can
detract from the results and interpretation;
● Name and signature of one or two authorised persons.
The signature may be generated electronically or
manually;
● Pagination (i.e. page 1 of 1 or page 1 of 2);
● It is helpful to draw attention to the limitations of the
analysis and any uncertainties of the result, especially
when the extent of analysis has not reached the standard
given in guidance documents;
● It is advisable to provide information regarding the
clinical consequences of the observed genetic aberra-
tions in the report. If a purely technical report is issued it
should be made clear that the referring clinician will
interpret the results and this must be clearly documented
elsewhere in the patient notes;
● Where abbreviated cytogenetic results are reported for
integration into a MDT-report, the information in the
abbreviated MDT result must be consistent with the full
cytogenetic report. The cytogenetic summary must be
authorised by a suitably qualiﬁed healthcare scientist. A
full version of the cytogenetic report must be sent
independently to the referring health specialist.
Analytical information
● The most recent version of ISCN should be used to
report the results of chromosome banded analysis,
including the number of cells;
● Single cell anomalies and heteromorphisms should not
be included in the ISCN, but may be reported in the
written description with qualiﬁcations;
● The FISH and array results may be given in either ISCN,
a tabular format or as a summary statement in a
prominent position on the report;
● The report must include the probe manufacturer, the
limitations of the test (probe set), whether the analysis of
the sample is restricted only to interphase cells (i.e. no
metaphase analysis done), the number of normal and
abnormal cells and whether the investigated material
consisted of cultured or uncultured cells (only if the
liquid sample has been cultured);
● Where complex results are given as a summary
statement, whether or not a clinically signiﬁcant
abnormality was detected should be stated. The full
results should be detailed elsewhere in the report;
● Cell numbers must be given for all FISH investigations
in neoplastic disorders regardless of whether they are
normal or abnormal, except for FFPE samples;
● It is preferable to describe the FISH results as normal or
abnormal. The term ‘positive’ or ‘negative’ must not be
used to describe the FISH result. Abnormal FISH results
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should be described as for example ‘KMT2A rearrange-
ment is present in xx cells’ or ‘3 copies of RUNX1
present in xx cells’ so that it is clear the result is not
normal;
● A written description of the results should be provided
including: the number of copies of any chromosome
missing or extra; description of any karyotype imbal-
ance resulting from unbalanced rearrangements; descrip-
tion of clinically relevant structural abnormalities,
including genes in the rearrangement. This is particu-
larly important if the results are given in ISCN which
may not be interpretable by the reader of the report;
● FISH manufacturer and array platform used should be
included in the report;
● The genome build, if required, should be included either
in the ISCN or appear elsewhere in the report for
abnormal results;
● Limitations of the test(s) used should be given.
Interpretation
● Relationship of any abnormalities found to the referral
reason, or other possible disease association where
appropriate (differential diagnosis, abnormality not
related to referral reason);
● Although mosaic trisomy 8 can be constitutional, it is
not considered necessary to attempt to exclude this in
the majority of cases where an extra chromosome 8 is
found as the sole abnormality in a myeloid disorder.
When reporting –Y or +15 it should be made clear that
these changes can be found in elderly patients with no
haematological neoplasm [91–93];
● The WHO 2017 nomenclature should be used in relation
to the disease category, where appropriate [1];
● The generic term “malignancy” should not be used in
the context of a clone of unknown signiﬁcance. The
term ‘chromosomally aberrant clone’ is recommended
instead;
● Prognosis if robust data from multiple publications/
international trials/trial protocols exists: e.g. evidence
from large randomised control trials of patients under-
going similar relevant treatment or meta-analysis/
systematic review of multiple studies. Multiple
concordant studies can be used and should be
referenced, Small and isolated studies should not be
used to derive prognosis;
● Recommendations for other investigations (e.g. FISH) to
clarify signiﬁcance of the results.
Reporting times
The guidance in Table 4 (below) is for maximum reporting
times and it is expected that the majority of referrals will be
reported well within these times. The laboratory should
have contingencies for providing rapid reporting of some
results.
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